Sublingual immunotherapy in the treatment of children.
Children with controlled intermittent mild-to-moderate asthma, controlled rhinitis and a single sensitivity may be appropriate candidates for sublingual immunotherapy (SLIT). Positive effects of SLIT may depend on initiation in early childhood and a long duration of treatment. To ensure optimum compliance, sociological, economic and familial factors should also be taken in to consideration when prescribing SLIT. Evidence from recent long-term trials indicates that SLIT interfered with the atopic march and the allergic progression from rhinitis to asthma without any severe adverse side effects. Local immune response has been seen to be blunted with SLIT, which suggests that treatment has an immunomodulatory effect. In addition, it may also decrease the risk of new sensitizations. Ongoing developments in SLIT, particularly advances in dosing and new indications, such as food allergies, will increase the use of this treatment modality in children.
Pham-Thi
N
N
Service de Pneumologie et Allergologie Pédiatriques, Hôpital Necker-Enfants Malades, Paris, France.
de Blic
J
J
Scheinmann
P
P
D000286:Administration, Sublingual; D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology; D001249:Asthma / Q000276:immunology / Q000628:therapy*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003888:Desensitization, Immunologic; D004334:Drug Administration Schedule; D006801:Humans; D010349:Patient Compliance; D010372:Pediatrics; D012220:Rhinitis / Q000276:immunology / Q000628:therapy*
D000485:Allergens